Awareness, value and use of the Australian living guidelines for the clinical care of people with COVID-19 : an impact evaluation
Copyright © 2021. Published by Elsevier Inc..
BACKGROUND AND OBJECTIVE: The Australian National COVID-19 Clinical Evidence Taskforce is developing living, evidence-based, national guidelines for treatment of people with COVID-19. These living guidelines are updated each week. We undertook an impact evaluation to understand the extent to which health professionals providing treatment to people with COVID 19 were aware of, valued and used the guidelines, and the factors that enabled or hampered this.
METHODS: A mixed methods approach was used for the evaluation. Surveys were conducted to collect both quantitative and qualitative data and were supplemented with qualitative interviews. Australian healthcare practitioners potentially providing care to individuals with suspected or confirmed COVID-19 were invited to participate. Data were collected on guideline awareness, relevance, ease of use, trustworthiness, value, importance of updating, use, and strengths and opportunities for improvement.
RESULTS: A total of 287 people completed the surveys and 10 interviews were conducted during November 2020. Awareness of the work of the Taskforce was high and the vast majority of respondents reported that the guidelines were very or extremely relevant, easy to use, trustworthy and valuable. More than 50% of respondents had used the guidelines to support their own clinical decision-making; and 30% were aware of other examples of the guidelines being used. Qualitative data revealed that amongst an overwhelming morass of evidence and opinions during the COVID-19 pandemic, the guidelines have been a reliable, united source of evidence-based advice; participants felt the guidelines built confidence and provided reassurance in clinical decision-making. Opportunities to improve awareness and accessibility to the guidelines were also explored.
CONCLUSIONS: As of June 2021, the guidelines have been published and updated more than 40 times, include more than 140 recommendations and are being used to inform clinical decisions. The findings of this impact evaluation will be used to improve processes and outputs of the Taskforce and guidelines project, and to inform future living guideline projects.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:143 |
|---|---|
| Enthalten in: |
Journal of clinical epidemiology - 143(2022) vom: 30. März, Seite 11-21 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Millard, Tanya [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Australia |
|---|
| Anmerkungen: |
Date Completed 03.05.2022 Date Revised 21.12.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jclinepi.2021.11.035 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM333891465 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM333891465 | ||
| 003 | DE-627 | ||
| 005 | 20231225222557.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jclinepi.2021.11.035 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1112.xml |
| 035 | |a (DE-627)NLM333891465 | ||
| 035 | |a (NLM)34852274 | ||
| 035 | |a (PII)S0895-4356(21)00393-0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Millard, Tanya |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Awareness, value and use of the Australian living guidelines for the clinical care of people with COVID-19 |b an impact evaluation |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 03.05.2022 | ||
| 500 | |a Date Revised 21.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021. Published by Elsevier Inc. | ||
| 520 | |a BACKGROUND AND OBJECTIVE: The Australian National COVID-19 Clinical Evidence Taskforce is developing living, evidence-based, national guidelines for treatment of people with COVID-19. These living guidelines are updated each week. We undertook an impact evaluation to understand the extent to which health professionals providing treatment to people with COVID 19 were aware of, valued and used the guidelines, and the factors that enabled or hampered this | ||
| 520 | |a METHODS: A mixed methods approach was used for the evaluation. Surveys were conducted to collect both quantitative and qualitative data and were supplemented with qualitative interviews. Australian healthcare practitioners potentially providing care to individuals with suspected or confirmed COVID-19 were invited to participate. Data were collected on guideline awareness, relevance, ease of use, trustworthiness, value, importance of updating, use, and strengths and opportunities for improvement | ||
| 520 | |a RESULTS: A total of 287 people completed the surveys and 10 interviews were conducted during November 2020. Awareness of the work of the Taskforce was high and the vast majority of respondents reported that the guidelines were very or extremely relevant, easy to use, trustworthy and valuable. More than 50% of respondents had used the guidelines to support their own clinical decision-making; and 30% were aware of other examples of the guidelines being used. Qualitative data revealed that amongst an overwhelming morass of evidence and opinions during the COVID-19 pandemic, the guidelines have been a reliable, united source of evidence-based advice; participants felt the guidelines built confidence and provided reassurance in clinical decision-making. Opportunities to improve awareness and accessibility to the guidelines were also explored | ||
| 520 | |a CONCLUSIONS: As of June 2021, the guidelines have been published and updated more than 40 times, include more than 140 recommendations and are being used to inform clinical decisions. The findings of this impact evaluation will be used to improve processes and outputs of the Taskforce and guidelines project, and to inform future living guideline projects | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Australia | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a GRADE | |
| 650 | 4 | |a Impact evaluation | |
| 650 | 4 | |a Living evidence synthesis | |
| 650 | 4 | |a evidence-based guidelines | |
| 700 | 1 | |a Elliott, Julian H |e verfasserin |4 aut | |
| 700 | 1 | |a Green, Sally |e verfasserin |4 aut | |
| 700 | 1 | |a Tendal, Britta |e verfasserin |4 aut | |
| 700 | 1 | |a Vogel, Joshua P |e verfasserin |4 aut | |
| 700 | 1 | |a Norris, Sarah |e verfasserin |4 aut | |
| 700 | 1 | |a Tate, Rhiannon |e verfasserin |4 aut | |
| 700 | 1 | |a Turner, Tari |e verfasserin |4 aut | |
| 700 | 0 | |a National COVID-19 Clinical Evidence Taskforce |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of clinical epidemiology |d 1991 |g 143(2022) vom: 30. März, Seite 11-21 |w (DE-627)NLM012614815 |x 1878-5921 |7 nnns |
| 773 | 1 | 8 | |g volume:143 |g year:2022 |g day:30 |g month:03 |g pages:11-21 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jclinepi.2021.11.035 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 143 |j 2022 |b 30 |c 03 |h 11-21 | ||